Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Chao Family Comprehensive Cancer Center, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00600002
First received: January 17, 2008
Last updated: July 1, 2013
Last verified: July 2013
  Purpose

The application of immunotherapeutic strategies that target the most potent antigen presenting cell, the dendritic cell (DC), are likely to substantially increase the magnitude of the anti-tumor immune response. Although there are issues of activation state and antigen load, mechanisms to increase the number of DCs available to the immune system are among the first steps in development of affective DC based immunotherapeutic strategies. The Central Hypothesis of our study is: Administration of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) to patients with pancreatic adenocarcinoma will result in enhance recruitment of DCs to the sentinel lymph node, into the peripheral blood, and/or tumor site. We propose performing a phase I, dose escalation, clinical trial of systemic and intra-tumoral GM-CSF administration for the treatment of pancreatic adenocarcinoma. This trial will be designed to assess toxicity and immunologic effects, principally dendritic cell recruitment. Patients with resectable pancreatic adenocarcinoma by clinical staging criteria will be eligible for enrollment.

The trial we propose is a phase I clinical trial of the addition of GM-CSF as a biological adjuvant to standard care for patients with potentially resectable pancreatic adenocarcinoma.


Condition Intervention Phase
Resectable Pancreatic Adenocarcinoma
Pancreatic Cancer
Biological: GM-CSF
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • Evaluate toxicity, dendritic cell recruitment, and immune parameters [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluate patient survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Evaluate progression free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Evaluate time to treatment failure [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Evaluate quality of life [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Evaluate biochemical markers [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: June 2004
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GM-CSF
Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
Biological: GM-CSF
Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histological proven adenocarcinoma of the pancreas with potentially resectable disease based upon clinical staging.
  • Expected survival must be greater than three (3) months.
  • A Karnofsky Performance Status (KPS) must be 70 or greater.
  • Patients must be >18 years of age. Because Leukine® is a "Pregnancy Category C" drug, female patients must be not be lactating and must be surgically sterile (via hysterectomy or bilateral tubal ligation), postmenopausal, or using acceptable methods of contraception if they are of child bearing potential. Female patients of childbearing potential must also have a negative serum pregnancy test.
  • Patients must be able to understand and sign an informed consent form, which must comply with U.S. regulations (U.S. 21 Code of Federal Regulations (CFR) 50) and International Conference on Harmonisation (ICH) guidelines. Availability of alternative curative treatment must be fully explained to the patient and documented in the informed consent form.
  • Eligible patients must meet the following laboratory parameters:
  • White blood cell (WBC) >3,000/mm3
  • Platelets >100,000/mm3
  • Hct >33% or Hgb >10.5 gm/dL
  • Prothrombin time (PT) within 3 seconds of control
  • Serum creatinine <1.5 mg/dL
  • Serum calcium <11.0 mg/dL
  • Serum Amylase < 2 times the upper limit of normal
  • Negative HIV-Ag and HIV-Ab

Exclusion Criteria:

  • Patients who have undergone previous treatment with a biological response modifier (interferons, interleukins) or prior immunotherapy within four (4) weeks of study enrollment.
  • Patients currently requiring corticosteroids, under immune suppression for any reason including an organ allograft.
  • Patients with known contraindications to analgesia or endoscopy.
  • Patients with unstable cardiovascular disease (Class IV cardiovascular disease according to the New York Heart Association's functional criteria).
  • Patients with any acute or chronic illness as judged clinically significant by the Investigators.
  • Patients who have received prior chemotherapy or radiation therapy to the thorax within four (4) weeks of enrollment.
  • Prior surgery within 30 days of execution of the informed consent form.
  • Persistent fever greater than 39 degrees Celsius unless clinical assessment attributes the etiology to be tumor.
  • Primary malignancy (present or remote) of sites other than the pancreas, except for the basal cell epithelioma of the skin.
  • Use of investigational drugs within 30 days of execution of the informed consent form.
  • Clinically significant (symptomatic) third space fluid collection (i.e.: ascites, pleural effusion).
  • Patients with a diagnosis of an autoimmune state, or any psychiatric illness that in the opinion of the Investigators would compromise treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00600002

Locations
United States, California
Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine
Investigators
Principal Investigator: Edward L Nelson, M.D. Chao Family Comprehensive Cancer Center
  More Information

No publications provided

Responsible Party: Chao Family Comprehensive Cancer Center, Cancer Center, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00600002     History of Changes
Other Study ID Numbers: UCI 02-69, 2003-2972
Study First Received: January 17, 2008
Last Updated: July 1, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Irvine:
GM-CSF
Leukine

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 26, 2014